The results of this cross-sectional study suggest that classifying invasive breast cancer by molecular subtypes based on hormone receptor and ERBB2 overexpression has been associated with several advancements in diagnosis and effective treatment in women as well as substantial improvements in quality of care and survival outcomes. This evidence concerns the gene NR4A1 and invasive breast carcinoma.